Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Drug: Bevacizumab Injection

Phase 3

SSummit Therapeutics

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Metastatic Colorectal Cancer (CRC)Recruiting

Metastatic Colorectal Cancer (CRC)Phase 3

Recruiting

Timeline

Expected Milestones

Q4 2029

Phase 3Recruiting

Metastatic Colorectal Cancer (CRC)

NCT07228832

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer (CRC)1 trial

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination With FOLFOX Versus Bevacizumab in Combination With FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer

Recruiting·SSummit Therapeutics·Phase 3·NCT07228832·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Drug: Bevacizumab Injection. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Drug: Bevacizumab Injection. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Summit Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: SSummit Therapeutics

Related News